Recent advances in oridonin derivatives with anticancer activity
Cancer is a leading cause of mortality responsible for an estimated 10 million deaths worldwide in 2020, and its incidence has been rapidly growing over the last decades. Population growth and aging, as well as high systemic toxicity and chemoresistance associated with conventional anticancer therap...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Chemistry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2023.1066280/full |
| _version_ | 1811168372216299520 |
|---|---|
| author | Pedro J. M. Sobral Pedro J. M. Sobral André T. S. Vicente Jorge A. R. Salvador Jorge A. R. Salvador |
| author_facet | Pedro J. M. Sobral Pedro J. M. Sobral André T. S. Vicente Jorge A. R. Salvador Jorge A. R. Salvador |
| author_sort | Pedro J. M. Sobral |
| collection | DOAJ |
| description | Cancer is a leading cause of mortality responsible for an estimated 10 million deaths worldwide in 2020, and its incidence has been rapidly growing over the last decades. Population growth and aging, as well as high systemic toxicity and chemoresistance associated with conventional anticancer therapies reflect these high levels of incidence and mortality. Thus, efforts have been made to search for novel anticancer drugs with fewer side effects and greater therapeutic effectiveness. Nature continues to be the main source of biologically active lead compounds, and diterpenoids are considered one of the most important families since many have been reported to possess anticancer properties. Oridonin is an ent-kaurane tetracyclic diterpenoid isolated from Rabdosia rubescens and has been a target of extensive research over the last few years. It displays a broad range of biological effects including neuroprotective, anti-inflammatory, and anticancer activity against a variety of tumor cells. Several structural modifications on the oridonin and biological evaluation of its derivatives have been performed, creating a library of compounds with improved pharmacological activities. This mini-review aims to highlight the recent advances in oridonin derivatives as potential anticancer drugs, while succinctly exploring their proposed mechanisms of action. To wind up, future research perspectives in this field are also disclosed. |
| first_indexed | 2024-04-10T16:26:18Z |
| format | Article |
| id | doaj.art-e46468c5b35b4d2c97b9e0b37488b68b |
| institution | Directory Open Access Journal |
| issn | 2296-2646 |
| language | English |
| last_indexed | 2024-04-10T16:26:18Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Chemistry |
| spelling | doaj.art-e46468c5b35b4d2c97b9e0b37488b68b2023-02-09T06:36:16ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462023-02-011110.3389/fchem.2023.10662801066280Recent advances in oridonin derivatives with anticancer activityPedro J. M. Sobral0Pedro J. M. Sobral1André T. S. Vicente2Jorge A. R. Salvador3Jorge A. R. Salvador4Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, PortugalCenter for Neuroscience and Cell Biology, University of Coimbra, Coimbra, PortugalLaboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, PortugalLaboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, PortugalCenter for Neuroscience and Cell Biology, University of Coimbra, Coimbra, PortugalCancer is a leading cause of mortality responsible for an estimated 10 million deaths worldwide in 2020, and its incidence has been rapidly growing over the last decades. Population growth and aging, as well as high systemic toxicity and chemoresistance associated with conventional anticancer therapies reflect these high levels of incidence and mortality. Thus, efforts have been made to search for novel anticancer drugs with fewer side effects and greater therapeutic effectiveness. Nature continues to be the main source of biologically active lead compounds, and diterpenoids are considered one of the most important families since many have been reported to possess anticancer properties. Oridonin is an ent-kaurane tetracyclic diterpenoid isolated from Rabdosia rubescens and has been a target of extensive research over the last few years. It displays a broad range of biological effects including neuroprotective, anti-inflammatory, and anticancer activity against a variety of tumor cells. Several structural modifications on the oridonin and biological evaluation of its derivatives have been performed, creating a library of compounds with improved pharmacological activities. This mini-review aims to highlight the recent advances in oridonin derivatives as potential anticancer drugs, while succinctly exploring their proposed mechanisms of action. To wind up, future research perspectives in this field are also disclosed.https://www.frontiersin.org/articles/10.3389/fchem.2023.1066280/fulloridoninditerpenoid derivativesanticancer activitydrug discoverystructural modification |
| spellingShingle | Pedro J. M. Sobral Pedro J. M. Sobral André T. S. Vicente Jorge A. R. Salvador Jorge A. R. Salvador Recent advances in oridonin derivatives with anticancer activity Frontiers in Chemistry oridonin diterpenoid derivatives anticancer activity drug discovery structural modification |
| title | Recent advances in oridonin derivatives with anticancer activity |
| title_full | Recent advances in oridonin derivatives with anticancer activity |
| title_fullStr | Recent advances in oridonin derivatives with anticancer activity |
| title_full_unstemmed | Recent advances in oridonin derivatives with anticancer activity |
| title_short | Recent advances in oridonin derivatives with anticancer activity |
| title_sort | recent advances in oridonin derivatives with anticancer activity |
| topic | oridonin diterpenoid derivatives anticancer activity drug discovery structural modification |
| url | https://www.frontiersin.org/articles/10.3389/fchem.2023.1066280/full |
| work_keys_str_mv | AT pedrojmsobral recentadvancesinoridoninderivativeswithanticanceractivity AT pedrojmsobral recentadvancesinoridoninderivativeswithanticanceractivity AT andretsvicente recentadvancesinoridoninderivativeswithanticanceractivity AT jorgearsalvador recentadvancesinoridoninderivativeswithanticanceractivity AT jorgearsalvador recentadvancesinoridoninderivativeswithanticanceractivity |